Company intelligence / Profile preview

Sara

Worcester, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Sara Therapeutics is a pre-clinical stage biotechnology company dedicated to developing transformative RNA-based therapies for neurodegenerative diseases. The company utilizes a proprietary hydrophobic siRNA (hsiRNA) platform designed to achieve broad and efficient delivery throughout the central nervous system without the need for complex delivery vehicles. Its lead program focuses on Huntington's disease, aiming to selectively silence the mutant huntingtin gene. By leveraging advanced oligonucleotide chemistry, Sara Therapeutics seeks to address high unmet medical needs in neurology.

Therapeutic areas: Neurology
Modalities: Small interfering RNARNA therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Sara.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sara.

Explore the full profile